Dementia Drugs Market Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027

1. DEMENTIA DRUGS MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027 © Coherent market Insights. All Rights Reserved © Coherent market Insights. All Rights Reserved

2. REPORT DESCRIPTION Dementia Drugs - Overview The Global Dementia Drugs Market, by Drug Class (MAO Inhibitors, Cholinesterase Inhibitors, and Glutamate Inhibitors) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others) was valued at US$ 13,900.0 million in 2017 and is estimated to exhibit a CAGR of 8.4% over the forecast period (2018-2026). The increasing number of people suffering from early stage of Alzheimer’s disease with dementia do not have proper access to healthcare infrastructure for diagnosis and treatment of the disease, globally. For instance, according to the World Alzheimer Report in 2016, only around 50% patients suffering from dementia undergo diagnosis. The rate of underdiagnoses is 10% in low and middle-income economies, and this is expected to drive growth of the dementia drugs market over the forecast period. Moreover, as of 2011, there were no standard guidelines for diagnosis of disease. Currently, biomarker tests involving amount of beta-amyloid in the brain, which can be visualized in positron emission tomography imaging are under research to diagnosis and develop treatment for Alzheimer’s disease. Browse 25 Market Data Tables and 44 Figures spread through 173 Pages and in-depth TOC on "Dementia Drugs Market, by Drug Class (MAO Inhibitors, Cholinesterase Inhibitors, and Glutamate Inhibitors) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others) - Global Forecast to 2026" Browse Research Reports: https://www.coherentmarketinsights.com/market- insight/dementia-drugs-market-1664 © Coherent market Insights. All Rights Reserved

3. REPORT DESCRIPTION The market is expected to witness significant growth over the forecast period, attributed to advancing diagnostic capabilities and growing awareness about dementia, among populace. Moreover, disease-modifying mechanisms are expected to enhance the treatment of this neurodegenerative condition. As a global push is made for early diagnosis and treatment, the surge in dementia cases will require effective therapies. Furthermore, market players are increasingly focusing on receiving the FDA approvals for their products, which is further expected to boost the market growth over the forecast period. For instance, in September 2017, Zydus Cadila received approval from the U.S. FDA to market Donepezil Hydrochloride tablets used for the treatment of dementia of the Alzheimer’s type in the U.S. In addition, several market players are focusing on developing novel drugs, in order to strengthen their market position, globally. For instance, in 2016, Merck and Company bought an exclusive worldwide license from Japan's Teijin Pharma to develop an investigational, preclinical anti-tau antibody, which has disease-modifying potential. Similarly, Genentech and AC immune are developing anti-tau antibody. Furthermore, in 2017, TauRx announced phase three results of investigational drug LMTX first tau aggregation inhibitor for Alzheimer’s disease. However, failure of drugs in late stages of clinical trials is the major factor that is expected to hinder growth of the market over the forecast period. Request a Sample copy of this reports :https://www.coherentmarketinsights.com/insight/request-sample/1664 © Coherent market Insights. All Rights Reserved

4. REPORT DESCRIPTION Key takeaways of the dementia drugs market: • 8.4% over the forecast period (2018-2026). This is attributed to increasing incidence of dementia, across the globe especially in Asia Pacific, coupled with increasing number of government initiatives to provide better palliative care to patients. The global dementia drugs market is expected to exhibit a CAGR of • significant growth over the forecast period, owing to monoamine oxidase-B (MAO-B) inhibitor, which is less toxic compared to cholinesterase inhibitor and has a concomitant extension of life span Among drug class, MAO inhibitors segment is expected to witness • Eisai, Inc., Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Inc.., Valeant Pharmaceutical International, Pfizer Inc., and Teva Pharmaceuticals Industries Ltd, among others. Key players operating in the global dementia drugs market include Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1664 © Coherent market Insights. All Rights Reserved

5. ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES CUSTOMIZED RESEARCH INDUSTRY ANALYSIS SYNDICATED RESEARCH COUNTRY SPECIFIC STUDIES MARKET INTELLIGENCE SERVICES CONSULT STUDIES © Coherent market Insights. All Rights Reserved

6. ABOUT CMI SECTOR COVERAGE BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL DEVICES MEDICAL IMAGING PHARMACEUTICAL OUR CLIENTS  Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators  Private and Government organization  Distributors, Retailors and Value Added Resellers  Outsourcing Companies  Healthcare IT Solutions Developers  Universities and Business Schools. © Coherent market Insights. All Rights Reserved

7. KEY STATS RESEARCH SOLUTIONS 100+ GLOBAL REPORTS FEASIBILITY STUDIES Insights Published Per Year CUSTOMIZED SOLUTIONS 150+ COUNTRY ANALYSIS Consulting Projects Till Date CONSULT PROJECTS SURVEY RESEARCH 125+ EXCEL FORECAST DATABASE Clients Worldwide Per Year COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS 110+ Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

8. THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702 © Coherent market Insights. All Rights Reserved